PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	10/510,229
Filing Date	October 13, 2004
First Named Inventor	REITER Yoram et al
Art Unit	Not yet available
Examiner Name	
Attorney Docket Number	28429

Sheet | | of |

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. [1]	Document Number Number-Kind Code [2] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
ZL	1	US-5,952,471	09-14-1999	Griffiths Lawson	
	2	US-6,416,738	09-9-2002	Theodore et al.	
	3	US-2003/0165993	04-4-2003	Buechler et al.	
	4	US-5,591,829	07-7-1997	Matsushita	
	5	US-2003/0129191	07-10-2003	Theodore et al.	
	6	US-2003/0223994	04-4-2003	Hoogenboom et al.	
ZL	7	US-5,695,928	09-9-1997	Stewart et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. [1]	Foreign Patent Documents Country Code [3] Number [4] Kind Code [5] (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [6]
ZL	8	PCT WO 2004/084798	07-7-2004	Reiter et al.		

Examiner Signature	/Zachariah Lucas/	Date Considered	12/27/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. [1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (08-03)
Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	10/510,229
Filing Date	October 10, 2004
First Named Inventor	REITER Yoram et al
Group Art Unit	Not yet available
Examiner Name	
Attorney Docket Number	28429

Sheet | | Of | |

Examiner Initials	Cite No.[1]	OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
ZL	9	Reiter et al. "Peptide-Specific Killing of Antigen-Presenting Cells by A Recombinant Antibody-Toxin Fusion Protein Targeted to Major Histocompatibility Complex/Peptide Class I Complexes With T Cell Receptor-Like Specifity", Proc. Natl. Acad. Sci. USA, 94(9): 4631-4636, 1997.	
	10	Andersen et al. "A Recombinant Antibody With the Antigen-Specific, Major Histocompatibility Complex-Restricted Specifity of T Cells", Proceedings of the National Academy of Sciences, 93(5): 1820-1824, 1996.	
	11	Rudikoff et al. "Single Amino Acid Substitution Altering Antigen-Binding Specifity", Proceedings of the National Academy of Sciences, USA, 79(6): 1979-1983, 1982.	
	12	Stedman Definition "Fab Fragment", Stedman's Online Medical Dictionary, 27th Edition. Www.stedmans.com. No Date available	
	13	??? Definition "Fab", The Online Medical Ddictionary, cancerweb.ncl.ac.uk/omd/. No Date availal	
	14	Engberg et al. "Recombinent Antibodies With the Antigen-Specific, MHC Restricted Specifity of T Cells: Novel Reagents for Basic and Clinical Investigations and Immunotherpy", Immunotechnology, 4(Nos.3-4): 273-278, 1999.	
	15	Saito et al. "In Vivo Selection of T-Cell Receptor Junctional Region Sequences by HLA-A2 Human T-Cell Lymphotropic Virus Type 1 Tax11-19 Peptide Complexes", Journal of Virology, 75(2): 1065-1071, 2001.	
	16	Polakova et al. "Antibodies Directed Against the MHC-I Molecule H-2Dd Complexed With An Antigenic Peptide: Similarities to A T Cell Receptor With the Same Specifity", The Journal of Immunology, 165: 5703-5712, 2000.	
	17	Chung et al. "Competitive Inhibition In Vivo and Skewing of the T Cell Repertoire of Antigen-Specific CTL Priming by an Anti-Peptide-MHC Monoclonal Antbody", The Journal of Immunology, 167: 699-707, 2001.	
	18	Robert et al. "Antibody-Conjugated MHC Class I Tetramers Can Target Tumor Cells For Specific lysis by T Lumphocytes", European Journal of Immunology, 30: 3165-3170, 2000.	
	19	Yoshida et al. "Isolation And Characterization Of Retrovirus From Cell Lines Of Human Adult T-Cell Leukemia And Its Implication In the Disease", PNAS, 79:2031-2035, 1982.	
	20	Köhler et al. "Continuous Cultures Of Fused Cells Secreting Antibody Of Predefined Specificity", Nature, 256:495-497, 1975.	
	21	Harding et al. "Quantitation Of Antigen-Presenting Cell MHC Class II/ Peptide Complexes Necessary For T-Cell Stimulation", Nature, 346: 574-576, 1990.	
	22	Christinck et al. "Peptide Binding To Class I MHC On Living Cels And Quantitation of Compplexes Required For CTL Lysis", Nature, 352: 67-70, 1991.	
	23	Aharoni et al. "Immunomodulation Of Experimental Allergic Encephalomyelitis By Antibodies To The Antigen-la Complex", Nature, 351: 147-149, 1991.	
	24	Haard et al. "A Large Non-Immunized Human Fab Fragment Phage Library That Permits Rabipd Isolation And Kinetic Analysis Of High Affinity Antibodies", The Journal of Biological Chemistry, 274(26): 18218-18230, 1999.	
	25	Winter et al. "Man-Made Antibodies", Nature, 349: 293-299, 1991.	
	26	Stubbs et al. "Influence Of Core Fucosylation On TheFlexibility Of A Biantennary N-Linked Oligosaccharide", Bichemistry, 35: 937-947, 1996.	
ZL	27	Hoogenboom et al. "By-Passing Immunisation - Human Antibodies From Synthetic Repertoires Of Germline VH Gene Segments Rearranged In Vitro", Journal of Molecular Biology, 227: 381-388, 1992.	

/Zachariah Lucas/ 12/27/2006

ZL	28	Grassmann et al. "Transformation To Continuous Growth Of Primary Human T Lymphocytes By Human T-Cell Leukemia Virus Type I X-Region Genes Tranduced By A Herpesvirus Saimiri Vector", PNAS, 86: 3351-3355, 1989.	
	29	Poiesz et al. "Detection And Isolation Of Type C Retrovirus Particles From Fresh And Cultured Lymphocytes Of A Patient With Cutaneous T-Cell Lymphoma", PNAS, 77(12): 7415-7419, 1980.	
	30	Porter "The Hydrolysis Of Rabbit γ-Globulin And Antibidies With Crystalline Papain", Biochemical Journal, 73: 119-126, 1959.	
	31	Pozzatti et al. "The Human T-Lymphotropic Virus Type I "Tax" Gene Can Cooperate With The "Ras" Oncogene To Induce Neoplastic Transformation Of Cells", Molecular and Cellular Biology, 10(1): 413-417, 1990.	
	32	Neuberger "Generating High-Avidity Human Mabs InMice", Nature Biotechnology, 14, 1996.	
	33	Bird et al. "Single-Chain Antigen-Binding Proteins", Science, 242: 423-426, 1988.	
	34	Marks et al. "By-Passing Immunization - Human Antibodies From V-Gene Libraries Displayed On Phage", Journal ofMelcular Biology, 222: 581-597, 1991.	
	35	Cote et al. "Generation Of Human Monoclonal Antibodies Reactive With Cellular Antigens", PNAS, 80: 2026-2030, 1983.	
	36	Murphy et al. "A Novel MHC Class II Epitope Expressed In Thymic Medulla But Not Cortex", Nature, 338:765-768, 1989.	
	37	Riechmann et al. "Reshaping Human Antibodies For Therapy", Nature 332: 323-327, 1988.	
	38	Bieganowska et al. "Direct Analysis Of Viral-Specific CD8 T Cells With Soluble HLA-A2/Tax11-19 Tetramer Complexes in Patients With Human T-Cell Lymphotropic Virus-Associated Myelopathy", he Journal of Immunology, 162:1765-1771, 1999.	
	39	Anton et al. "MHC Class I-Associated Peptides Produced From Endogenous Gene Products With Vastly Different Efficiencies", The Journal of Immunology, 158: 2535-2542, 1997.	
	40	Altman et al. "Phenotypic Analysis Of Antegen-Specific T Lymphocytes", Science, 274:94-96, 1996.	
	41	Chames et al. "Direct Selection Of A Human Antibody Fragment Directed Against The Tumor T-Cell Epitope HLA-A1-MAGE-A1 From A Nonimmunized Phage-Fab Library", PNAS, 97(14): 7969-7974, 2000.	
	42	Demotz et al. "The Minimal Number Of Class II MHC-Antigen Complexes Needed For T Cell Activation", Science, 249: 1028-1030, 1990.	
	43	Boerner et al. "Production Of Antigen-Specific Human Monoclonal Antibodies From In-Vitro-Primed Human Splenocytes", The Journal of Immunology, 147(1): 86-95, 1991.	
	44	Morrison "Success In Specification",Nature, 368:812-813,1994.	
	45	Jones et al. "Replacing The Complementarity-Determining Regions On A Human Antibody With Those From a Mouse", Nature, 321:522-525,1986.	
	46	Verhoeyen et al. "Reshaping Human Antiodies: Grafting an Antilysozyme Activity", Science, 239: 1534-1536, 1988.	
	47	Rosenberg Nature, 411: 380-384, 2001.	
	48	Lonberg et al. "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic Modifications", Nature, 368, 856-859, 1994.	
ZL	49	Verhoeyen et al. "Reshaping Human Antibodies: Grafting An Antilysozyme Activity", Science, 239, 1534-1536,1988.	

Signature	/Zachariah Lucas/	Considered	12/27/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1]. Applicant's unique citation designation number (optional). [2]. Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.